Your session is about to expire
← Back to Search
Other
Orforglipron for Obesity
Phase 3
Waitlist Available
Research Sponsored by Eli Lilly and Company
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Must not have
Acute or chronic hepatitis
History of acute or chronic pancreatitis
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
Pivotal Trial
Summary
"This trial aims to test how well orforglipron helps people to keep off weight they have lost, and whether it is safe to use for this purpose."
Who is the study for?
This trial is for individuals who are overweight or have obesity with related health issues. It's designed to see if they can maintain weight loss after initial reduction. Specific eligibility details aren't provided, but typically participants must meet certain health criteria and not be taking conflicting medications.
What is being tested?
The study is testing the effectiveness of a drug called Orforglipron in helping people keep off weight they've already lost. Participants will either receive Orforglipron or a placebo (a substance with no active drug) to compare results.
What are the potential side effects?
While specific side effects of Orforglipron are not listed here, common ones for weight maintenance drugs may include gastrointestinal issues, headaches, dizziness, and potential changes in mood or sleep patterns.
Eligibility Criteria
Exclusion Criteria
You may be eligible for the trial if you check “No” for criteria below:Select...
I have hepatitis.
Select...
I have a history of pancreatitis.
Select...
I have a history of diabetes or severe diabetic complications.
Select...
I have had or am planning to have surgery for weight loss.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 5 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
Treatment Details
Awards & Highlights
Pivotal Trial
The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
Trial Design
2Treatment groups
Experimental Treatment
Placebo Group
Group I: OrforglipronExperimental Treatment1 Intervention
Participants will receive orforglipron orally
Group II: PlaceboPlacebo Group1 Intervention
Participants will receive placebo orally
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Orforglipron
2024
Completed Phase 1
~80
Find a Location
Who is running the clinical trial?
Eli Lilly and CompanyLead Sponsor
2,680 Previous Clinical Trials
3,466,084 Total Patients Enrolled
69 Trials studying Obesity
46,787 Patients Enrolled for Obesity
Study DirectorEli Lilly and Company
1,391 Previous Clinical Trials
428,541 Total Patients Enrolled
52 Trials studying Obesity
25,592 Patients Enrolled for Obesity